A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?

Gretchen A. McNally,Connor M. Aossey,Tracy Wiczer,Loraine T. Sinnott,Mark Lustberg,Robert A. Baiocchi,Maryam Lustberg

DOI: https://doi.org/10.1080/10428194.2024.2340051

2024-04-23

Leukemia & Lymphoma

Abstract:The frontline immuno-chemotherapy regimen for HIV-associated non-Hodgkin Lymphoma is dose-adjusted EPOCH ± R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). Chemotherapy-induced peripheral neuropathy (CIPN), caused by vincristine, is a common adverse effect of EPOCH ± R, negatively impacting long-term patient outcomes. The primary objective of this study was to determine the incidence of CIPN, stratified by HIV status, in patients treated with EPOCH ± R. A retrospective cohort study at a tertiary referral comprehensive cancer center evaluated patients treated with EPOCH ± R from 2011 to 2018. The final sample included 27 patients with HIV compared to 279 without HIV (total n = 306). Overall, the incidence of CIPN was 29.4% ( n = 90), including 5 with HIV (18.5%) and 85 without HIV (30.5%). Propensity scores were used to match patients by HIV status. Although no relationship was found between HIV status and neuropathy, CIPN affects too many undergoing treatments for lymphoma, supporting future investigations to minimize toxicities.

oncology,hematology

What problem does this paper attempt to address?

This paper aims to explore the frequency of chemotherapy - induced peripheral neuropathy (CIPN) in non - Hodgkin lymphoma (NHL) patients treated with the EPOCH ± R regimen, and pay special attention to whether HIV status affects the incidence of this side effect. Specifically, the main objective of the study was to determine the incidence of CIPN in NHL patients receiving EPOCH ± R treatment and perform a stratified analysis according to HIV status. In addition, the study also attempted to describe the factors associated with the development of CIPN.

### Research Background
Chemotherapy - induced peripheral neuropathy is a neurological side effect caused by certain chemotherapy drugs and is common in patients treated with the EPOCH ± R regimen. The EPOCH ± R regimen includes etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab, among which vincristine is one of the main components causing CIPN. People living with HIV may be more likely to develop peripheral neuropathy due to the virus itself, inflammatory responses, opportunistic infections, and the neurotoxic effects of antiretroviral drugs. However, specific data on the incidence of CIPN in people living with HIV when receiving EPOCH ± R treatment are still insufficient.

### Research Methods
This was a retrospective cohort study. The study subjects were NHL patients who received EPOCH ± R treatment at the Arthur G. James Cancer Hospital of The Ohio State University between 2011 and 2018. The study collected patients' baseline characteristics, symptom assessments during treatment, and the occurrence of CIPN through the electronic medical record system. The definition of CIPN was based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4, and a grade greater than 0 was considered as the presence of CIPN.

### Research Results
A total of 306 patients were included in the study, including 27 HIV - infected patients and 279 non - HIV - infected patients. Overall, the incidence of CIPN was 29.4% (90 patients), including 5 HIV - infected patients (18.5%) and 85 non - HIV - infected patients (30.5%). After propensity score matching, there was no statistically significant difference in the incidence of CIPN between HIV - infected and non - HIV - infected patients (p = 0.58). The only baseline characteristic significantly associated with the occurrence of CIPN was white race (p = 0.04).

### Discussion
Although people living with HIV are generally considered more likely to develop peripheral neuropathy, the results of this study showed that in NHL patients receiving EPOCH ± R treatment, there was no significant difference in the incidence of CIPN between HIV - infected and non - HIV - infected patients. This may be due to the combined effects of multiple factors, including the use of antiretroviral drugs, racial differences, and the overall health status of patients. Future studies should further explore the risk factors and biological markers of CIPN to improve the treatment experience and quality of life of patients.

### Conclusion
This study is the first to evaluate the incidence of CIPN in HIV - infected and non - HIV - infected patients when receiving EPOCH ± R treatment. Although the incidence of CIPN in HIV - infected patients is lower, CIPN remains an important clinical problem that affects the quality of life of many patients. Future studies should continue to explore the risk factors and preventive measures of CIPN, especially in HIV - infected patients.